Stockpolly
Search
RAPP · NASDAQ · Biotechnology

Rapport Therapeutics (RAPP)

Develops RAP-targeted neuromedicines, with RAP-219 advancing across seizure and bipolar mania programs.

$48.69
At close+0.13 (+0.27%)
Watchlist

Something off on this page? Send us feedback.

Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$1.21
Revenue estimate
—
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.68−$0.75−$0.71−$0.72−$0.42−$1.19−$1.19Pending
Estimate−$0.77−$0.87−$0.77−$0.65−$0.56−$1.12−$0.96−$1.21
Surprise+11.7%+13.8%+7.8%−10.8%+25.0%−6.2%−23.6%—

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported————$20.0M——Pending
Estimate————$7.5M$2.2M$2.2M—
Surprise————+166.7%———

History

DateEstimateReportedSurprise
Nov 2026−$1.21——
Aug 2026−$0.96−$1.19−23.6%
Aug 2026−$1.12−$1.19−6.2%
May 2026−$0.56−$0.42+25.0%
Mar 2026−$0.65−$0.72−10.8%

The latest year is open to everyone — the 11 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 5, 2026−$1.21——————
Aug 6, 2026−$0.96−$1.19−23.6%$2.2M——−1.9%
Aug 5, 2026−$1.12−$1.19−6.2%$2.2M——+0.6%
May 7, 2026−$0.56−$0.42+25.0%$7.5M$20.0M+166.7%−4.7%
Mar 10, 2026−$0.65−$0.72−10.8%———+3.1%

The latest year is open to everyone — the 11 quarters behind it read with an account.

Sign in
Nov 6, 2025
Aug 7, 2025
May 8, 2025
Mar 11, 2025
Nov 7, 2024
Aug 8, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 29, 2023
Mar 31, 2023